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ABSTRACT
Background: Varenicline, a new treatment for smoking
cessation, has demonstrated significantly greater efficacy
over placebo and sustained release bupropion (bupropion
SR). A study was undertaken to compare a 12-week
standard regimen of varenicline with a 10-week standard
regimen of transdermal nicotine replacement therapy
(NRT) for smoking cessation.
Methods: In this 52-week, open-label, randomised,
multicentre, phase 3 trial conducted in Belgium, France, the
Netherlands, UK and USA, participants were randomly
assigned (1:1) to receive varenicline uptitrated to 1 mg
twice daily for 12 weeks or transdermal NRT (21 mg/day
reducing to7 mg/day) for 10 weeks. Non-treatment follow-
up continued to week 52. The primary outcome was the
biochemically confirmed (exhaled carbon monoxide
(10 ppm) self-reported continuous abstinence rate (CAR)
for the last 4 weeks of the treatment period in participants
who had taken at least one dose of treatment. Secondary
outcomes included CAR from the last 4 weeks of treatment
through weeks 24 and 52, and measures of craving,
withdrawal and smoking satisfaction.
Results: A total of 376 and 370 participants assigned to
varenicline and NRT, respectively, were eligible for
analysis. The CAR for the last 4 weeks of treatment was
significantly greater for varenicline (55.9%) than NRT
(43.2%; OR 1.70, 95% CI 1.26 to 2.28, p,0.001). The
week 52 CAR (NRT, weeks 8–52; varenicline, weeks
9–52) was 26.1% for varenicline and 20.3% for NRT
(OR 1.40, 95% CI 0.99 to 1.99, p=0.056). Varenicline
significantly reduced craving (p,0.001), withdrawal
symptoms (p,0.001) and smoking satisfaction
(p,0.001) compared with NRT. The most frequent
adverse event was nausea (varenicline, 37.2%; NRT,
9.7%).
Conclusions: The outcomes of this trial established that
abstinence from smoking was greater and craving,
withdrawal symptoms and smoking satisfaction were less
at the end of treatment with varenicline than with
transdermal NRT.
Trial registration number: NCT00143325.
Smoking cessation treatments are among the most
cost-effective disease prevention interventions
available.
1 Many smokers want to quit smoking,
but unaided quit attempts have 1-year success
rates of only 3–5%.
23Pharmacological treatments
approved for smoking cessation in the USA and the
European Union include various forms of nicotine
replacement therapy (NRT), sustained-release (SR)
bupropion and, most recently, varenicline.
145
Compared with placebo, NRT and bupropion SR
approximately double the odds of remaining
abstinent 6–12 months after quitting,
67 while
varenicline raises the odds by 2.5–3 times com-
pared with placebo 12 months after quitting.
8–10
Bupropion SR and NRT are both recognised as
first-line pharmacotherapies for smoking cessation
in the US and Europe,
14and the most commonly
used in the UK and the USA is NRT.
11 12 Direct
comparison of varenicline with bupropion SR in
two double-blind clinical trials showed that var-
enicline had significantly greater efficacy than
bupropion SR at the end of 12 weeks of treatment
and at 6 months of follow-up,
81 0and one of these
studies showed continued significant efficacy at 1-
year follow-up.
10 Smoking cessation treatment
with varenicline also resulted in greater verified
abstinence 4 weeks after quitting than single-use
NRT treatment in a historical comparison of
consecutive routine cases before and after the
introduction of varenicline.
13
We report the results of the first randomised
clinical trial comparing varenicline with transder-
mal nicotine. The primary objective of the present
study was to compare a 12-week standard regimen
of varenicline with a 10-week standard regimen of
transdermal NRT for smoking cessation using an
open-label design.
METHODS
Study design
This was an open-label randomised trial conducted
in 24 centres in Belgium (4 sites), France (6 sites),
The Netherlands (4 sites), UK (4 sites) and USA (6
sites). Ethical approval was gained from
Independent Review Boards for each centre. The
study, conducted from 17 January 2005 to 28 June
2006, complied with the ethical principles of the
Declaration of Helsinki and the International
Conference on Harmonization Good Clinical
Practices Guidelines. All participants provided
written informed consent prior to any procedures.
Study population
Participants were all motivated to stop smoking
and were recruited in smoking cessation clinics or
via local advertising. They were smokers, 18–75
years of age, weight .45.5 kg and body mass index
15–38 kg/m
2. Each participant smoked at least 15
cigarettes per day with no period of abstinence
.3 months in the previous year. Female smokers
were eligible providing they were not breastfeed-
ing, pregnant or at risk of becoming pregnant.
Smoking
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other serious or unstable disease within the previous
6 months, diagnoses of or treatment for depression or other
psychological disorder, or drug or alcohol dependence within
the previous 12 months. Other exclusion criteria were
clinically significant allergic reactions to drugs or adhesive
tapes, skin disorders, systolic blood pressure .150 mm Hg or
diastolic blood pressure .95 mm Hg, clinically significant
renal or hepatic impairment, evidence of liver dysfunction or
other abnormal laboratory tests. Participants were also
excluded if they were taking medication that may interfere
with the study outcome, had previously participated in a
varenicline study in the previous year or had used of any form
of NRT in the previous 6 months.
Interventions
After screening, eligible participants were invited to a baseline
visit. Using a central computer-generated sequence, they were
randomised in a 1:1 ratio to either 12 weeks of treatment with
varenicline or 10 weeks of treatment with a nicotine transder-
mal patch (as per the manufacturer’s recommendation).
14 15
Participants were provided with an educational booklet on
smoking cessation entitled ‘‘Clearing the air: how to quit smoking
… and quit for keeps’’ at the baseline visit and took part in a brief
((10 min) counselling session in accordance with the US Public
Health Service Guidelines.
1 Counselling also occurred during
every subsequent telephone and clinic visit.
The target quit date (TQD) coincided with the week 1 visit in
both treatment groups. Varenicline treatment began 1 week
before the TQD (the day after the baseline visit) whereas NRT
treatment began on the TQD as per the manufacturer’s
recommendations. Participants randomised to varenicline were
administered 0.5 mg/day for 3 days, 0.5 mg twice daily for
4 days, then 1 mg twice daily thereafter. Full dosing was achieved
by the TQD and continued for a further 11 weeks. Participants
randomised to NRT applied transdermal patches (NicoDerm CQ
Clear (GlaxoSmithKline) in the USA and NiQuitin CQ Clear
(GlaxoSmithKline) in Europe) each morning starting on the TQD
for 10 weeks. Doses of NRT were 21 mg/day for
the first 6 weeks, 14 mg/day for 2 weeks, then 7 mg/day for
2 weeks (as per the manufacturer’s recommendation). During the
treatment phase, participants received a contact telephone call
3 days after the TQD and attended the clinic on a weekly basis
commencing in week 1 (fig 1).
The non-treatment follow-up phase of the study totalled
41 weeks for NRT participants and 40 weeks for varenicline
participants. Visits to the clinic (weeks 13, 16, 24, 32, 40, 48 and
52) were interspersed with telephone calls (weeks 14, 20, 28, 36
and 44).
Study end points
Efficacy
The primary end point was the self-reported continuous
abstinence rate (CAR), confirmed by exhaled carbon monoxide
(CO) levels of 10 ppm or below, during the last 4 weeks of
treatment (varenicline, weeks 9–12; NRT, weeks 8–11).
Secondary efficacy end points included CO-confirmed CAR
for the last 4 weeks of treatment through weeks 24 and 52
(varenicline, weeks 9–24 and 9–52; NRT, weeks 8–24 and 8–52).
Abstinence from smoking during the preceding 7 days and
confirmed by CO measures (7-day point prevalence of
abstinence) was also assessed at the end of treatment and at
the week 24 and week 52 visits.
Measures of craving and withdrawal
The Minnesota Nicotine Withdrawal Scale (MNWS)
16 17
assessed urge to smoke, depressed mood, irritability, anxiety,
poor concentration, restlessness, increased appetite and insom-
nia. The modified Cigarette Evaluation Questionnaire
(mCEQ)
18 19 recorded measures of smoking satisfaction, psycho-
logical reward, enjoyment of respiratory tract sensations,
craving reduction and aversion.
Both these questionnaires were completed at the baseline visit
and at each weekly visit through week 7, or at termination for
participants who discontinued the study before week 7. While
the MNWS was completed by all participants, the mCEQ was
only completed by participants who reported smoking since
their last completed questionnaire. The MNWS was also
completed on TQD+3.
Safety evaluations
Blood chemistry, haematology, urinalysis tests, vital signs,
physical examinations, body weight measures and electrocar-
diograms were assessed during the treatment period. All
observed or self-reported adverse events were recorded and
followed up until resolution or the end of study. Any adverse
event that was life-threatening or resulted in hospitalisation,
persistent or significant disability, incapacity or death was
considered a serious adverse event, as was a medical or surgical
intervention to prevent one of these outcomes.
Statistical analysis
A sample size of 365 participants per group was estimated to
provide at least 90% power to detect a difference between
varenicline and NRT for the last 4 weeks of treatment CAR
based on an odds ratio (OR) of 1.75 (assuming NRT cessation
rate of 24%) and for the week 52 CAR based on an OR of 2.00
(assuming NRT cessation rate of 11.5%).
Figure 1 Study design. W, week;
TQD, target quit date; Rand,
randomisation; NRT, nicotine replacement
therapy; BID, twice daily.
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analysed using a logistic regression model, including terms for
treatment and centre. Participants were classified as smokers or
non-smokers for each end point and analyses were of abstinence
rates. To be classified as a non-smoker, participants had to have
not used any nicotine-containing product (other than a
transdermal patch in the NRT group) during the treatment
phase or any tobacco products during the follow-up phase. Use
of NRT during the 9 months of follow-up did not disqualify a
subject from being a responder provided other conditions were
met. Participants who missed a visit but had otherwise met the
criteria since the last visit were considered non-smokers.
Missing CO data were assumed to be (10 ppm provided other
conditions were met. Participants who withdrew from the
study were assumed to be smokers for the remainder of the
study, regardless of their smoking status at the last visit.
Efficacy and safety analyses were conducted on randomised
participants who received at least one dose of study medication
(Primary Analysis Population). As a prespecified sensitivity
analysis, identical analysis of CAR values was also conducted
using the All Randomised Population, which additionally
included any randomised participants who withdrew before
receiving study drug. Owing to the 1-week difference in
treatment duration, additional prespecified sensitivity analyses
were conducted with 4-week CAR values for weeks 8–11, 9–12
and with week 52 CAR starting from week 8 and week 9 for
both treatment groups.
The ORs and 95% confidence intervals (CIs) are estimates
from the logistic regression model of CAR. The likelihood ratio
x
2 test was used and significance tests were two-tailed, a=0.05.
The additional effect of treatment-by-centre interaction was
determined from an expanded logistic model. A post hoc
assessment of the effect of country was conducted using an
expanded logistic model including treatment, country and
treatment-by-country interaction.
Subscales of the MNWS and the mCEQ were analysed as
continuous variables from the TQD through week 7. The
analyses were based on a repeated measures model with
Figure 2 Participant disposition. NRT, nicotine replacement therapy.
Smoking
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interaction as factors. Model estimates on the average effect and
p values were obtained by contrasting the average scores over
week 1 through week 7. No imputation for missing subscale
scores at individual visits was conducted. SAS V.8.2 (SAS
Institute, Cary, North Carolina, USA) was used for all analyses.
RESULTS
Participants
A total of 957 participants were screened for the study and 757
were randomised (378 varenicline; 379 NRT). Of these, 376
varenicline participants and 370 NRT participants reported
taking at least one dose of treatment medication. The
progression of participants through the study is shown in fig 2.
The demographic characteristics and smoking histories were
comparable between treatment groups (table 1).
Efficacy
End of treatment 4-week CAR
For the Primary Analysis Population (all randomised and
treated), the proportion of participants who remained con-
tinuously abstinent for the last 4 weeks of treatment was
significantly greater for varenicline (weeks 9–12, 55.9%
(n=210)) than for NRT (weeks 8–11, 43.2% (n=160); OR
1.70, 95% CI 1.26 to 2.28, p,0.001; fig 3). The results were
similar for the All Randomised Population (varenicline, 55.6%;
NRT, 42.2%; OR 1.76, 95% CI 1.31 to 2.36, p,0.001) and were
also similar when the two treatments were compared in the
same 4-week periods: weeks 9–12 (varenicline, 55.9%; NRT,
42.2%; OR 1.78, 95% CI 1.32 to 2.39, p,0.001) and weeks 8–11
(varenicline, 55.1%; NRT, 43.2%; OR 1.64, 95% CI 1.22 to 2.21,
p,0.001).
CAR through week 24
In the Primary Analysis Population, week 24 CAR (NRT, weeks
8–24; varenicline, weeks 9–24) was higher for varenicline
(32.4%) than for NRT (27.3%) but the difference was not
significant (OR 1.29, 95% CI 0.94 to 1.77, p=0.118). The results
were similar in the All Randomised Population (varenicline,
32.2%; NRT, 26.6%; OR 1.33, 95% CI 0.97 to 1.82, p=0.081).
CAR through week 52
In the Primary Analysis Population, week 52 CAR (NRT, weeks
8–52; varenicline, weeks 9–52) was also higher for varenicline
(26.1%; n=98) than for NRT (20.3%; n=75; OR 1.40, 95% CI
0.99 to 1.99, p=0.056; fig 4). The results were similar in the All
Randomised Population but the difference at week 52 was
significant (varenicline, 25.9%; NRT, 19.8%; OR 1.44, 95% CI
1.02 to 2.03, p=0.040).
CAR by study centre and country
There was no significant treatment-by-centre interaction for
the 4-week end of treatment CAR or for week 52 CAR (NRT,
weeks 8–52; varenicline, weeks 9–52), supporting the general-
isation of combined results across centres in which this study
was conducted. Post hoc analyses showed evidence of a
treatment-by-country interaction for the end of treatment
CAR (p=0.009, table 2) but not through week 52 (p=0.306).
Additional post hoc analyses were performed to investigate the
treatment-by-country interaction. There were no significant
interactions for treatment-by-baseline characteristics (all nom-
inal p values were .0.10 for the following categories:
Fagerstro ¨m test for nicotine dependence score, smoking rate,
previous quit attempt with NRT or with transdermal patch).
Stratification by previous NRT patch use indicated that the
estimated varenicline treatment effect versus NRT was numeri-
cally greater in individuals who had previously used NRT,
although the interaction tests were not significant (p=0.155 for
end of treatment CAR and p=0.681 through week 52).
However, previous use of NRT did not account for the
between-country differences in the relative efficacy of vareni-
cline at the end of treatment or through week 52.
7-day point prevalence of abstinence
The 7-day point prevalence of abstinence score at week 12 in the
Primary Analysis Population was significantly higher for
varenicline (62.0%) than for NRT (47.0%; OR 1.71, 95% CI
1.27 to 2.30, p,0.001). There were no significant differences at
week 24 (varenicline, 38.6%; NRT, 34.1%; OR 1.22, 95% CI 0.90
Table 1 Demographic characteristics and smoking history
Parameter
Varenicline
(n=376)
NRT
(n=370)
Mean (SD) age (years) 42.9 (10.5) 42.9 (12.0)
Mean (SD) height (cm) 171.9 (9.6) 171.6 (9.2)
Mean (SD) weight (kg) 76.4 (15.9) 75.6 (14.1)
Gender (%)
Male 48.4 50.0
Female 51.6 50.0
Race (%)
Caucasian 92.6 93.5
Black 2.9 1.6
Asian 2.1 2.4
Other 2.4 2.4
Mean (range) duration of smoking (years) 25.9 (2–58) 25.2 (1–62)
Mean (range) cigarettes per day over last
month (n)
23.0 (15–80) 22.4 (11–60)
1 or more previous serious quit attempts (%) 86.1 89.7
Previous attempts with nicotine patch (%) 48.5 46.2
Previous attempts with bupropion (%) 19.7 20.0
Mean (range) longest previous period of
abstinence (days)
5.64 (0–90) 7.49 (0–90)
Mean (SD) Fagerstro ¨m test for nicotine
dependence score
5.62 (2.23) 5.37 (1.99)
Figure 3 Four-week end of treatment CAR (weeks 9–12 for varenicline
and weeks 8–11 for NRT) for the Primary Analysis Population (all
randomised and treated participants who took at least one dose of study
medication). Results of the All Randomised Population CAR for the same
period: varenicline, 55.6%; NRT, 42.2% (OR 1.76, 95% CI 1.31 to 2.36;
p,0.001). CAR, continuous abstinence rate; NRT, nicotine replacement
therapy; OR, odds ratio; CI, confidence intervals.
Smoking
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31.4%; OR 1.18, 95% CI 0.87 to 1.62, p=0.285).
Craving, withdrawal symptoms and reinforcement
Scores in the urge to smoke subscale of the MNWS were lower
for varenicline than for NRT at each weekly time point. When
these data were averaged over weeks 1–7, varenicline scores
were significantly lower than NRT scores (p,0.001), indicating
that varenicline reduced craving further than NRT. Varenicline
also showed significantly lower scores in the negative effect
(p,0.001) and restlessness (p,0.001) subscales of the MNWS,
but not the increased appetite or insomnia subscales (table 3).
Compared with NRT, varenicline participants reported
significantly lower smoking satisfaction (p,0.001), psychologi-
cal reward (p=0.001), enjoyment of respiratory tract sensations
(p,0.001) and craving reduction (p,0.001) in the average week
1–7 scores of the mCEQ. There was no significant difference
between the aversion subscale scores for the two groups
(table 4).
Safety
Overall, treatment-emergent adverse events were experienced
by 84.8% of the varenicline group and 70.3% of the NRT group
(table 5). Most adverse events were reported as mild or
moderate in intensity. The all-cause treatment-emergent
adverse events are summarised in table 5. The most frequent
adverse events in both treatment groups were nausea, insomnia,
headache and abnormal dreams. Severe adverse events were
experienced by 9.8% of the varenicline group and 7.3% of the
NRT group. The most commonly reported severe adverse events
were nausea (varenicline, n=7; NRT, n=0), headache (vareni-
cline, n=5; NRT, n=0) and insomnia (varenicline, n=5; NRT,
n=1).
Table 5 shows permanent discontinuations from study
medications due to adverse events and temporary withdrawal
from or reduction in doses of study medication due to
treatment-emergent adverse events. The most frequent adverse
event leading to treatment discontinuation was nausea (vareni-
cline, 2.1%; NRT, 0.8%). No other adverse event resulted in
treatment discontinuation in .1% of the population.
Ten participants experienced serious adverse events while
receiving treatment. One participant in the varenicline group
had depression that was attributed to the study drug.
Treatment was discontinued. Another participant in the
varenicline group had constipation that was not considered
related to study medication. The remaining eight participants
were in the NRT group and experienced bile duct cancer and
sepsis; gastrointestinal bleeding; myocardial infarction (n=2);
salivary gland tumour; chest pain (n=2); and worsening of
existing knee trauma. None of these serious adverse events was
attributed to NRT.
Three participants experienced serious adverse events during
the non-treatment follow-up phase. In the varenicline group,
one participant experienced acute ethanol intoxication. A
woman in the varenicline group experienced suicidal ideation
which resulted in hospitalisation 11 days after completing the
varenicline treatment. She had stopped smoking and was
experiencing family turmoil; she had a history of moodiness,
but no diagnosed disorder. The study investigator considered
this case to be attributable to the study drug. In the NRT group,
one participant experienced an abdominal cyst that was not
considered to be related to NRT. No participants died during the
study.
There were no permanent discontinuations of study medica-
tion as a result of laboratory test abnormalities and no clinically
relevant differences were shown between treatment groups for
any laboratory test. One participant in the varenicline group
had a raised liver function test reading at the end of treatment
but was then lost to follow-up so no additional testing was
conducted.
The mean change in body weight from baseline to the end of
treatment for all participants (regardless of smoking status) was
1.82 kg for varenicline (week 12, n=262) and 1.62 kg for NRT
(week 11, n=229). The mean change in body weight for
participants who remained continuously abstinent for the last
4 weeks of treatment was 2.02 kg (n=188) for varenicline and
2.07 kg (n=131) for NRT.
DISCUSSION
In this open-label study, smokers motivated to quit had
significantly higher abstinence rates during the last 4 weeks of
treatment when treated with 12 weeks of varenicline than with
10 weeks of transdermal NRT. The CAR for both treatment
groups was similar for the pre-specified Primary Analysis
Population and the All Randomised Population and the superior
treatment effect of varenicline was also evident with similar
effect sizes at week 11 (end of NRT treatment) and at week 12
(end of varenicline treatment). The CAR difference did not
Figure 4 CAR through week 52 (weeks 9–52 for varenicline and weeks
8–52 for NRT) for the Primary Analysis Population (all randomised and
treated participants who took at least one dose of study medication).
Results of the All Randomised Population CAR for the same period:
varenicline, 25.9%; NRT, 19.8% (OR 1.44, 95% CI 1.02 to 2.03;
p=0.040). CAR, continuous abstinence rate; NRT, nicotine replacement
therapy; OR, odds ratio; CI, confidence intervals.
Table 2 Continuous abstinence rate by country over last 4 weeks of treatment
Last 4 weeks of treatment
Country
Belgium France The Netherlands UK USA
Varenicline (weeks 9–12), n/N (%) 26/55 (47.3) 18/35 (51.4) 39/65 (60.0) 67/116 (57.8) 60/105 (57.1)
NRT (weeks 8–11), n/N (%) 31/53 (58.5) 11/31 (35.5) 38/64 (59.4) 35/115 (30.4) 45/107 (42.1)
NRT, nicotine replacement therapy.
Smoking
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varenicline, weeks 9–52) in the Primary Analysis Population.
The 7-day point prevalence of abstinence rates were similar to
the CAR outcomes.
Many researchers consider an intent-to-treat approach, where
the analysis population includes all randomised participants
regardless of whether they actually received study drug
treatment, as the gold standard for reporting most clinical
trials. However, we report the Primary Analysis Population
(those who were randomised and took at least one dose of
medication) in the efficacy results as this was our prespecified
primary analysis population. These results may underestimate
the efficacy of varenicline relative to NRT because of differential
dropout after medication assignment (ie, more participants
withdrew from the study after randomisation and before
receiving a first dose of medication in the NRT group (n=9;
2%) than in the varenicline group (n=2; 0.5%)). Since this was
an open-label study, the differential dropout may have been due
to dissatisfaction with treatment assignment. Consequently, it
is important to include the results of the prespecified analyses
for both populations. The All Randomised analyses statistically
favour varenicline over NRT at the end of treatment CAR and
week 52 CAR (NRT, weeks 8–52; varenicline, weeks 9–52).
The odds of abstinence at the end of open-label treatment for
varenicline over NRT (OR 1.70) is the same as that reported for
abstinence 4 weeks after the quit date in the comparison of
varenicline versus NRT in consecutive routine cases before and
after the introduction of varenicline.
13 This also approximates
recent varenicline versus bupropion SR double-blind compar-
isons showing ORs of 1.90 and 1.93 at the end of treatment.
81 0
In the longer term (over 52 weeks) the OR of remaining
abstinent with open-label varenicline versus NRT in this study
was 1.40, which is similar to the OR for double-blind varenicline
versus bupropion SR through week 52 in one previous study
Table 3 Measures of withdrawal and craving using the Minnesota Nicotine Withdrawal Scale (MNWS):
repeated measures analysis of data for weeks 1–7
N LS Mean (SE)*
Varenicline vs NRT
Difference (SE) 95% CI p Value Effect size{
Varenicline
Urge to smoke 367 1.35 (0.04) 20.32 (0.06) –0.44 to 20.21 ,0.001 –0.37
Negative effect 369 0.63 (0.03) –0.16 (0.04) –0.24 to –0.07 ,0.001 –0.21
Restlessness 368 0.76 (0.04) –0.20 (0.05) –0.31 to –0.10 ,0.001 –0.21
Increased appetite 368 1.07 (0.04) 0.09 (0.06) –0.02 to 0.21 0.116 0.12
Insomnia 368 0.70 (0.04) 20.07 (0.05) –0.17 to 0.04 0.207 20.07
NRT
Urge to smoke 366 1.67 (0.04)
Negative effect 366 0.79 (0.03)
Restlessness 366 0.96 (0.04)
Increased appetite 364 0.97 (0.04)
Insomnia 366 0.76 (0.04)
NRT, nicotine replacement therapy.
*Higher scores indicate greater intensity of symptoms. Response scale: 0 (not at all) to 4 (extreme).
{Effect size, LS mean difference divided by the pooled SD at baseline (pooled by centre).
Table 4 Measurement of smoking reinforcement using the modified Cigarette Evaluation Questionnaire
(mCEQ): repeated measures analysis of data for weeks 1–7 only in those who had smoked since their last visit
N LS Mean (SE)*
Varenicline vs NRT
Difference (SE) 95% CI p Value Effect size{
Varenicline
Smoking satisfaction 361 2.73 (0.09) –0.54 (0.12) –0.77 to –0.31 ,0.001 –0.43
Psychological reward 361 2.30 (0.07) –0.32 (0.10) –0.51 to –0.13 0.001 –0.26
Enjoyment of respiratory
tract sensations
358 2.04 (0.08) –0.39 (0.11) –0.60 to –0.17 ,0.001 –0.25
Craving reduction 360 3.62 (0.10) –0.52 (0.14) –0.79 to –0.24 ,0.001 –0.32
Aversion 361 1.76 (0.07) –0.07 (0.09) –0.25 to 0.11 0.436 –0.08
NRT
Smoking satisfaction 354 3.27 (0.08)
Psychological reward 354 2.61 (0.07)
Enjoyment of respiratory
tract sensations
353 2.42 (0.08)
Craving reduction 354 4.14 (0.10)
Aversion 354 1.83 (0.06)
NRT, nicotine replacement therapy.
N, total number of participants contributing to the repeated measures analysis. To be included subjects must have completed a
questionnaire at baseline and at one or more post-baseline visits. This includes those who smoked during the first week of
treatment, which was before the target quit date.
*Higher scores indicate greater intensity of smoking effects. Response scale: 1 (not at all) to 7 (extreme).
{Effect size, LS mean difference divided by the pooled SD at baseline (pooled by centre).
Smoking
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8 and lower than in another study (1.77).
10 In a meta-
analysis of trials comparing transdermal NRT to placebo or no
patch, the estimated long-term abstinence rate (after 52 weeks
from the start of treatment with transdermal NRT) was 13.7%,
6
compared with the CAR of 20.3% through week 52 in the
present study. The reasons for the higher abstinence rates in this
study are unclear.
In a recent meta-analysis using indirect comparisons of
treatment effect versus placebos, varenicline was found to be
significantly superior to NRT at 3 months (OR 1.78) and at
12 months (OR 1.66) while bupropion SR versus NRT at
12 months showed no difference (OR 1.14). The direct
comparisons of varenicline versus NRT reported here are similar
to these indirect comparisons but with a lower difference at
12 months.
20
Preclinical studies have shown that varenicline acts as a
partial agonist at the a4b2 nicotinic acetylcholine receptor
(nAChR), with both agonist and antagonist effects.
21 22
Participants who continued to smoke in the varenicline group
reported a greater reduction in smoking satisfaction than
continuing smokers in the NRT group. This may reflect the
antagonist action of varenicline at a4b2 nAChRs which are
thought to mediate the reinforcing effects of nicotine. As an
agonist, nicotine would be expected to alleviate withdrawal
symptoms. In this study, varenicline showed significant benefit
over NRT in measures of craving and withdrawal by decreasing
the urge to smoke, negative effect and restlessness. These
findings are consistent with lower severity ratings of craving in
participants in a routine smoking cessation clinic taking
varenicline compared with those taking NRT,
13 and are
encouraging in terms of increasing the pharmacotherapy choices
for smokers who find it hard to cope with symptoms of
withdrawal during quit attempts. This benefit of a partial
agonist over a full agonist is perhaps surprising, but may be due
to the combined effect of nicotine concentrations from NRT
being lower than those obtained from regular smoking and
varenicline having a higher affinity than nicotine for the a4b2
nAChR.
Safety data for both treatment groups were consistent with
previous reports,
23 24 although the occurrence of adverse skin
reactions in the transdermal nicotine group in this study was
relatively low and may have been due to the exclusion of
participants with allergic reactions to adhesive tape and skin
disorders. The overall number of treatment discontinuations
due to adverse events in this study (8%) was similar to the
number reported in previous varenicline versus bupropion SR
comparator trials (8.6%
8 and 10.5%
10) and lower than the
numbers reported for bupropion SR (15.2%
8 and 12.6%
10).
Reports of nausea (37.2%), insomnia (21.3%), headache (19.1%)
and constipation (8.2%) were more frequent in this trial than
those previously reported. The outcomes of a pooled analysis of
the frequency of adverse events occurring in the two phase 3
comparator trials of varenicline versus bupropion SR were:
nausea (28.8% varenicline vs 9.9% bupropion SR); insomnia
(14.2% varenicline vs 21.5% bupropion SR); headache (14.2%
varenicline vs 11.1% bupropion SR); and constipation (7.2%
varenicline v 6.7% bupropion SR).
25 Some physiological side
effects reported by participants may be due to smoking
cessation rather than treatment medication. For example,
insomnia is a DSM IV (Diagnostic and Statistical Manual of
Mental Disorders, 4th edition) nicotine withdrawal symptom
26
and constipation has also been proposed as an additional
symptom of withdrawal from nicotine.
27 Weight gain is also
listed as a withdrawal symptom in DSM IV.
26 The mean weight
gain for participants in both treatment groups at the end of
treatment was similar, regardless of smoking status.
Limitations of the study
A limitation of this study was the open-label design. The
differential dropout rate after medication assignment and before
the first dose of treatment suggests that some motivational bias
may have influenced the results. Discontinuation for adverse
events was less likely with NRT than with varenicline, while a
refusal to participate further was less likely with varenicline
than with NRT. A double-blind design may have avoided such
biases. A truly blind comparison of varenicline tablets and NRT
patch would have required a double-dummy design using
identical active drug and placebo tablets and patches.
However, technical problems made it difficult to create NRT
and placebo patches that were indistinguishable from one
another in appearance and odour. Motivational influences are
likely to exist in a real-world setting and the outcomes of this
study show that varenicline is more effective than transdermal
nicotine in enhancing quit rates in an open-label setting.
13
There was a longer treatment duration with varenicline
(12 weeks) than with NRT (10 weeks), in accordance with the
prescribing guidelines for each product,
14 15 which may have led
to a treatment bias. However, a recent meta-analysis found no
benefit of prolonged transdermal NRT treatment beyond
8 weeks,
6 and the effect sizes of varenicline versus transdermal
NRT were similar in weeks 8–11 and weeks 9–12 of this study.
Missing CO measurements were imputed as (10 ppm so, if
all other criteria for abstinence were met, missing CO
confirmation did not change the status of participants to
smoker. However, this did not have any meaningful impact on
the results. An alternative method for imputing missing CO
measurements that is recommended by the Russell Standards
for analysis of smoking studies
28 is to impute the missing CO as
negative (not smoking for the CAR end points) if the
subsequent measurement is not positive and at least the last
Table 5 Summary of all-cause treatment-emergent adverse events
occurring in >5% of either treatment group
Parameter
Varenicline 1 mg
twice daily
(n=376)
Nicotine titrated from
21 mg patches
(n=370)
Any adverse event 319 (84.8) 260 (70.3)
Treatment discontinuations due to
adverse events
30 (8.0) 16 (4.3)
Dose reductions or temporary
withdrawal from study medication
44 (11.7) 25 (6.8)
Deaths 0 (0.0) 0 (0.0)
Serious adverse events 2 (0.5) 8 (2.2)
Most frequent adverse events
Nausea 140 (37.2) 36 (9.7)
Insomnia 80 (21.3) 71 (19.2)
Headache 72 (19.1) 36 (9.7)
Abnormal dreams 44 (11.7) 31 (8.4)
Constipation 31 (8.2) 9 (2.4)
Dizziness 28 (7.4) 13 (3.5)
Disturbance in attention 24 (6.4) 5 (1.4)
Vomiting 23 (6.1) 4 (1.1)
Diarrhoea 22 (5.9) 10 (2.7)
Flatulence 22 (5.9) 5 (1.4)
Dysgeusia 22 (5.9) 4 (1.1)
Abdominal pain (upper) 21 (5.6) 4 (1.1)
Fatigue 21 (5.6) 9 (2.4)
Data presented as n (%).
Smoking
Thorax 2008;63:717–724. doi:10.1136/thx.2007.090647 723measurement (ie, the week 52 measurement) is non-missing and
negative. If we apply this imputation method, the result is one
fewer NRT non-smoker in the end of treatment CAR and one
fewer varenicline non-smoker for the week 52 CAR (NRT,
weeks 8–52; varenicline, weeks 9–52).
Subject selection criteria may also limit the interpretation of
the results.
29 The superiority of varenicline over NRT may not
generalise to populations such as teenage smokers, medically
compromised smokers (eg, those with active cardiac problems)
or smokers with current psychiatric disorders. There were very
few non-Caucasian participants in this study, although recent
studies conducted in Taiwan, Korea and Japan have shown that
varenicline has significant efficacy over placebo in these
populations.
30 31
With regard to future directions for research, trials are
currently being conducted in participants with cardiovascular
disease (www.clinicaltrials.gov; identifier: NCT00282984) and
chronic obstructive pulmonary disease (www.clinicaltrials.gov;
identifier: NCT00285012). There is some limited evidence that
varenicline is effective and safe in adults receiving treatment for
mental illness.
13 However, given the strict exclusion criteria for
phase 3 trials, future studies should also evaluate the efficacy of
varenicline in other specific populations such as those with
psychiatric disorders and adolescent smokers.
In conclusion, in this open-label comparison of varenicline
with transdermal NRT, varenicline appeared to be safe and well
tolerated. Varenicline demonstrated significantly greater absti-
nence rates than NRT at the end of treatment, consistent with
previously reported trials of varenicline versus placebo and
bupropion SR.
81 0 In addition, varenicline showed a greater
reduction on measures of craving, withdrawal and feelings of
smoking satisfaction compared with NRT.
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